Cover Image

A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The INVESTMENT study

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Jeffrey D. Sharon, Roseanne Krauter, Ricky Chae, Adam Gardi, Maxwell Hum, Isabel Allen, Morris Levin
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Headache: The Journal of Head and Face Pain
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparing single‐ and repeat‐dose psilocybin with active placebo for migraine prevention in an exploratory randomized controlled clinical trial
by: Emmanuelle A. D. Schindler, et al.
Published: (2025)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial
by: Nathaniel M. Schuster, et al.
Published: (2025)

Eicosapentaenoic acid versus placebo as adjunctive therapy in chronic migraine: A randomized controlled trial
by: Ghader Mohammadnezhad, et al.
Published: (2024)

Effectiveness and tolerability of galcanezumab for migraine prevention in patients ≥65 years: A real‐life multicenter study
by: Julia Peris‐Subiza, et al.
Published: (2025)

Treatment effectiveness of galcanezumab versus traditional oral migraine preventive medications at 3 months: Results from the TRIUMPH study
by: Richard B. Lipton, et al.
Published: (2025)

Efficacy of galcanezumab in proline‐rich transmembrane protein 2 ( PRRT2 ) ‐associated familial hemiplegic migraine: A case series
by: Costanza Sottani, et al.
Published: (2024)

Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial
by: Muneto Tatsumoto, et al.
Published: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
by: Larry Charleston, et al.
Published: (2026)

The effect of vestibular rehabilitation in the management of vestibular migraine in adults: A systematic review and meta‐analysis
by: Jad El Ahdab, et al.
Published: (2025)

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study
by: Shivang Joshi, et al.
Published: (2026)

Machine learning models and classification algorithms in the diagnosis of vestibular migraine: A systematic review and meta‐analysis
by: Pablo D. Suarez‐Barcena, et al.
Published: (2025)

Correction to “Smartphone‐delivered progressive muscle relaxation for the treatment of migraine in primary care: A randomized controlled trial”
Published: (2025)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
by: Serena Laura Orr, et al.
Published: (2024)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
by: Koichi Ikeda, et al.
Published: (2025)

Integrating gepants into clinical practice for the acute treatment of migraine
by: Richard B. Lipton, et al.
Published: (2026)

Partial rebreathing is not effective for early treatment of migraine with aura attacks: Results of a double‐blind, randomized, controlled trial ( PAREMA1 )
by: Charly Gaul, et al.
Published: (2025)

Assessment of pharmacokinetic and pharmacodynamic interactions between zavegepant and sumatriptan: A phase 1, randomized, placebo‐controlled study in healthy adults
by: Rajinder Bhardwaj, et al.
Published: (2024)

Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials
by: Stephen D. Silberstein, et al.
Published: (2024)

Nonspecific oral medications versus anti–calcitonin gene‐related peptide monoclonal antibodies for migraine: A systematic review and meta‐analysis of randomized controlled trials
by: Jennifer Robblee, et al.
Published: (2024)

Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of zavegepant nasal spray in healthy adults from two phase 1 randomized, placebo‐controlled trials
by: Richard Bertz, et al.
Published: (2025)

Mapping the migraine: Intracranial recording of cortical spreading depression in migraine with aura
by: Graham A. McLeod, et al.
Published: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
by: Geneviève Tourigny‐Ruel, et al.
Published: (2026)

Exploring the relationship between pain catastrophizing and migraine in youth: A longitudinal clinical cohort study
by: Alexis Espanioli, et al.
Published: (2025)

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial
by: Anna Gryglas‐Dworak, et al.
Published: (2024)

Engagement and predictors of use of a smartphone app for migraine self‐management: A secondary analysis of the EMMA trial
by: Stefanie Lysk, et al.
Published: (2025)

The impacts of migraine on functioning: Results from two qualitative studies of people living with migraine
by: Rikki Mangrum, et al.
Published: (2024)

The effect of different exercise types on migraine frequency in individuals with migraine: A pilot study
by: Yunus Emre Meydanal, et al.
Published: (2025)

Functional impairment of chronic migraine with medication overuse: Secondary analysis from the Medication Overuse Treatment Strategy ( MOTS ) trial
by: Samantha C. Shao, et al.
Published: (2024)

IV dexamethasone as adjuvant therapy to metoclopramide for acute posttraumatic headache in the ED : A randomized controlled trial
by: Kareem Joudi, et al.
Published: (2026)

Evaluating associations of migraine‐related vertigo
by: Nazia Karsan, et al.
Published: (2025)

Three years of remote electrical neuromodulation (REN) acute treatment for migraine shows consistent effectiveness and no tachyphylaxis phenomenon
by: Stephanie J. Nahas, et al.
Published: (2025)

Evaluating the use of paracetamol to prevent fasting headache during the first week of Ramadan: A randomized, open‐label, clinical trial
by: Omar A. Almohammed, et al.
Published: (2024)

Afterimage duration differs for migraine with or without aura
by: Florian Rimmele, et al.
Published: (2025)

Mechanisms for mindfulness in migraine: Does catastrophizing matter?
by: Rebecca Erwin Wells, et al.
Published: (2024)

Useful considerations for treating migraine in patients with autism
by: Sinifunanya E. Nwaobi
Published: (2026)

Lifestyle triggers of migraine: Sleep restriction and caffeine lower the threshold for migraine‐like responses in rats in a sex‐specific manner
by: Gabriel Camargo de Oliveira, et al.
Published: (2026)

Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
by: Shuu‐Jiun Wang, et al.
Published: (2024)

No association between migraine and HLA alleles in a cohort of 13,210 individuals with migraine from the Danish Blood Donor Study
by: Inga Zalia Tummoszeit, et al.
Published: (2024)

Advancing toward precision migraine treatment: Predicting responses to preventive medications with machine learning models based on patient and migraine features
by: Chia‐Chun Chiang, et al.
Published: (2024)

Serum levels of autotaxin reveal its role as a novel biomarker of migraine
by: Alberto Ouro, et al.
Published: (2025)